{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004058","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.726881+00:00","generated_at":"2026-06-13T20:27:36.367523+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase","bullets":["Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.","Stockholders approved amendment increasing 2017 Plan share reserve by 435,000 to 5,285,000 shares.","Gary Fischetti, John Henneman, and Susan Vogt elected Class III directors until 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004058","json":"https://secwatch.observer/filing/0001171843-23-004058.json","markdown":"https://secwatch.observer/filing/0001171843-23-004058.md","text":"https://secwatch.observer/filing/0001171843-23-004058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/f8k_062123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:27:36.367523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68d47890fa","claim":"Anne Nunes was appointed as Senior Vice President, Chief Operations Officer at Anika Therapeutics, Inc..","evidence_excerpt":"On June 14, 2023, the Board appointed Anne Nunes, age 54, as the Company’s Senior Vice President, Chief Operations Officer, effective as of June 19, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Operations Officer"}],"fact_type":"executive_change"},{"claim_id":"3f61908073bf58b61700f05a5e397c72e74045eb","claim":"Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-14 meeting.","evidence_excerpt":"Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 11,873,054 227,519 51,162 1,168,309","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"9175906ad2418c783908054d9bcc1e5e36c3043c","claim":"Anika Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.","evidence_excerpt":"Stockholders voted as follows with respect to this ratification proposal: For Against Abstain Broker Non-Votes 13,279,828 27,825 12,391 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"cb2cb0b496d7310900af556b3adef0727de7c535","claim":"Anika Therapeutics, Inc. shareholders approved Amendment to the 2017 Amended and Restated Stock Incentive Plan to increase authorized shares by 435,000 at the 2023-06-14 meeting.","evidence_excerpt":"Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 9,807,584 2,331,160 12,991 1,168,309","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"d98e6a6442d94e9d58ce1f5946677ef42d619cc5","claim":"Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.","evidence_excerpt":"Stockholders voted, on a non-binding, advisory basis, as follows with respect to the frequency of future advisory votes on compensation paid to the Company's named executive officers: 1 Year 2 Years 3 Years Abstain 11,078,317 3,067 1,038,679 31,672","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"dc949fb7fb2999962614390517c3558e19aed628","claim":"Anika Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-14 meeting.","evidence_excerpt":"Stockholders voted as follows with respect to election of each of the director nominees identified in the Proxy Statement: Nominee For Against Abstain Broker Non-Votes Gary P. Fischetti 12,032,739 106,519 12,477 1,168,309 John B. Henneman, III 11,054,795 1,079,499 17,441 1,168,309 Susan L. N. Vogt 11,721,294 417,401 13,040 1,168,309","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}